KOSDAQBiotech & Pharma950260

INGENIA Therapeutics

₩22,050▲ 9.16%2026-11-18 close
Market Cap
₩1.1T
Turnover
₩14.7B
Volume
680K
Shares out.
49.4M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Milestone-driven turn to profit

Cumulative Q3 2026 net income turned positive, but revenue still rests on a single MSD licensing deal while R&D funding needs keep rising.

  1. 1

    Cumulative Q3 2026 DART figures show revenue of KRW 5 million, an operating loss of KRW 1.17 million, and net income of KRW 0.93 million, with net income turning positive from a year-earlier loss.

  2. 2

    Revenue comes from upfront and milestone payments tied to the IGT-427 license, leaving the company heavily dependent on partner MSD.

  3. 3

    Consolidated revenue was effectively zero in 2025, and no revenue was recorded in the first quarter of 2026.

  4. 4

    The share price of KRW 20,100 compares with the IPO price of KRW 12,000, and market capitalization is KRW 993.8 billion. The KRW 60 billion IPO raise has strengthened liquidity.

  5. 5

    The 2027 licensing target for the follow-on candidate IGT-303 and a rising R&D spending plan are the key variables for future results and cash flow.

02

Business structure

INGENIA Therapeutics (Reg.S) is a biotech founded in March 2018 in Boston that develops antibody drugs to repair and normalize damaged microvessels, building on core technology from KAIST and the Institute for Basic Science (IBS).

Its core mechanism is direct activation of the vascular stabilizing receptor TIE2, and the company aims to expand the platform from eye diseases to systemic conditions such as chronic kidney disease, pulmonary arterial hypertension, and solid tumors.

The lead asset, the retinal disease candidate IGT-427, was licensed in 2022 at the preclinical stage to UK-based EyeBio. After MSD acquired EyeBio in 2024, MSD became the partner and now directly leads two Phase 2b/3 trials in neovascular age-related macular degeneration.

Under this structure, INGENIA does not bear global development costs and instead receives stage-based milestones and future royalties. Its wholly owned chronic kidney disease candidate IGT-303 is in Phase 2a trials in Australia, New Zealand, and Korea.

Other programs include the glaucoma candidate IGT-302, the pulmonary arterial hypertension candidate IGT-627, and the trispecific cancer candidate IGT-532, all in research and development.

Existing eye-disease treatments focus mainly on suppressing abnormal vessel growth and leakage, whereas INGENIA emphasizes vascular stabilization as its point of differentiation. Among Korean biopharma peers, Hanmi Pharm and Yuhan served as comparison companies for the price-to-earnings benchmark used in the IPO.

03

Recent trends

Based on DART filings, cumulative third-quarter 2026 revenue was KRW 5 million and the operating loss was KRW 1.17 million, which is a continued loss versus the same period a year earlier but a smaller one. Net income for the same period was KRW 0.93 million, turning positive from a year-earlier loss.

Korean media reports attributed the swing to milestone receipts from the IGT-427 license. The revenue base remains small, so the improvement in profitability should not be read as a scale-up of the business.

Consolidated 2025 revenue was zero, with an operating loss of USD 23.38 million and a net loss of USD 18.60 million, according to a News Well report. Applying the average FY25 exchange rate of 1,422.2 won per dollar used by the exchange, that operating loss converts to roughly KRW 33.19 billion.

Revenue in 2024 included USD 2.59 million in operating income as upfront payment recognition continued, but once that recognition ended, 2025 revenue effectively fell to zero.

Korean media reported that no revenue was booked in the first quarter of 2026, with an operating loss of KRW 6.3 billion and a net loss of KRW 6.3 billion. The shares opened on August 18, 2026 at KRW 17,990, up 49.92% from the IPO price of KRW 12,000.

As of November 16, 2026 at 20:24 KST, the share price was KRW 20,100, down 4.74% on the day, with market capitalization of KRW 993.8 billion and trading value of KRW 5 billion.

04

Outlook

The main open questions center on clinical progress for IGT-427 and the licensing results of follow-on candidates. The company has set a target of FDA approval in 2029 and commercialization in 2030, after the Phase 3 stage of IGT-427.

The company stated that funding for the DME Phase 3 milestone tied to IGT-427 is secured for the second half of 2026. For the follow-on candidate IGT-303, the company is pursuing a global licensing deal in 2027 based on Phase 2a data.

On funding, IB Tomato analyzed that the IPO proceeds plus cash and equivalents at the end of June, roughly KRW 64.7 billion combined, fall short of the R&D plan for the next two to three years, which would require KRW 70 billion to KRW 80 billion in additional inflows.

In the same report, the company said it intends to fund R&D from existing cash and licensing income and does not plan separate external fundraising. Planned R&D spending rises each year, to KRW 12.5 billion in 2026, KRW 21.4 billion in 2027, and KRW 24.4 billion in 2028.

The prospectus estimated 2026 revenue of KRW 47.7 billion and operating and net income of KRW 14.5 billion each, but this differs widely from the cumulative third-quarter 2026 DART results.

Whether these estimates are reached and whether licensing deals are executed will be the key variables reflected in future filings.

05

Bull factors

Global trials led by MSD

MSD is directly leading two Phase 2b/3 trials of IGT-427 in neovascular age-related macular degeneration. A Korean pharma trade report put the value of this licensing deal at more than KRW 1 trillion. INGENIA does not bear development costs and instead receives milestones and royalties. Trials have continued after the partner changed from EyeBio to MSD, which is cited as a bullish factor.

Cumulative Q3 profit turnaround

Based on DART filings, cumulative Q3 2026 net income of KRW 0.93 million turned positive from a loss in the same period a year earlier. The operating loss narrowed to KRW 1.17 million. Media reports attribute the swing to licensing milestone receipts. The result may be read as an early sign of moving away from an operating deficit structure.

Pipeline expansion and funding

IGT-303 is in Phase 2a trials and has a 2027 global licensing target. The target indications are broadening from eye disease to chronic kidney disease, pulmonary arterial hypertension, and solid tumors.

The KRW 60 billion IPO raise is also cited as strengthening liquidity relative to the cash position at the end of June 2026.

06

Bear factors

Single-partner revenue concentration

Revenue in 2023 and 2024 came entirely from EyeBio and MSD, and the company itself flagged this concentration as a key risk in its registration statement. Revenue was effectively zero in 2025 and absent in the first quarter of 2026.

According to the company, the concentration may persist if clinical trials are delayed or partner negotiations fail.

R&D funding needs and equity erosion

Planned R&D spending rises to KRW 12.5 billion in 2026, KRW 21.4 billion in 2027, and KRW 24.4 billion in 2028. IB Tomato analysis indicates the IPO proceeds plus cash at the end of June would not cover the two- to three-year plan.

Total equity fell to KRW 15.6 billion at the end of the first quarter of 2026, with retained earnings at negative KRW 31.3 billion.

Weaker biotech demand at listing

The retail subscription ratio was 3.09 to 1, which trailed the hundreds- or thousands-to-one ratios seen in biotech IPOs earlier in 2026. Media reports described Korean biotech shares falling sharply around the August 2026 listing, with investor sentiment weakening. This demand backdrop could also affect the terms of any future fundraising.

07

Risk factors

Market sentiment

Korean biotech shares were reported to have weakened in sentiment around the listing. As of November 16, 2026, the share price fell 4.74% on the day and trading value was KRW 5 billion. Additional funding tools such as rights offerings or convertible bonds exist, but their terms depend on market conditions.

Clinical

Delays in the Phase 2b/3 trials of IGT-427 would push back milestone receipts. The 2027 licensing target for IGT-303 depends on Phase 2a data, so weaker results could delay that timeline. Clinical outcomes are widely cited as the key variable for the company's valuation.

Partnership and licensing

The company plans to diversify its revenue sources through licensing its follow-on pipeline. If partner negotiations fail, the current concentration would continue. Licensing income depends on development outcomes, so the timing of upfront and milestone payments remains uncertain.

08

Overall view

INGENIA Therapeutics recorded a net income turnaround on a cumulative third-quarter 2026 DART basis, but revenue is only KRW 5 million and its income structure remains concentrated in the licensing agreement with MSD.

Bullish factors include MSD-led Phase 2b/3 trials of IGT-427, the 2027 licensing target for IGT-303, and liquidity strengthened by the KRW 60 billion IPO raise.

Bearish factors include effectively zero revenue in 2025, a plan for R&D spending to rise each year from 2026 through 2028, and an external analysis that additional cash inflows are required.

The prospectus projection of KRW 47.7 billion in 2026 revenue differs widely from cumulative third-quarter DART results, so whether it is reached will become clear through future filings.

Clinical progress and the execution of follow-on licensing deals are the key variables determining the company's business prospects, and the market capitalization stands at KRW 993.8 billion.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 12 more articles and sources
  1. supple.kr
  2. ibtomato.com
  3. ibtomato.com
  4. sedaily.com
  5. newstopkorea.com
  6. kpanews.co.kr
  7. kpanews.co.kr
  8. newswell.co.kr
  9. biotimes.co.kr
  10. news.nate.com
  11. news.bizwatch.co.kr
  12. v.daum.net

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis